PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.

Abstract

To assess positron emission tomography/computed tomography (PET/CT)-guided neoadjuvant treatment with tislelizumab plus chemotherapy/chemoradiotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC). RATIONALE-213, a multicenter, open-label, two-cohort phase II study, enrolled 70 patients with resectable ESCC. After one induction chemotherapy cycle, patients were categorized as PET responders (PET maximum standardized uptake value decrease ≥35%) or PET nonresponders (<35%). Subsequently, all patients received three cycles of tislelizumab 200 mg intravenously. In addition, PET responders received chemotherapy and PET nonresponders received chemoradiotherapy as neoadjuvant treatment followed by surgery. The primary endpoint was pathological complete response (pCR) rate. As of October 25, 2024 (median follow-up 25.5 months), pCR rates were 30.0% (95% CI, 11.9-54.3) in PET responders and 34.4% (95% CI, 18.6-53.2) in PET nonresponders. Higher pCR rates associated with higher baseline programmed cell death ligand 1 (PD-L1) Tumor Area Positivity (TAP) scores in both cohorts. One-year disease-free survival rates were 79.0% and 74.2%, and event-free survival rates were 87.1% and 67.8% respectively. Any-grade and grade ≥3 treatment-related adverse events (TRAEs) occurred in 93.3% and 50.0% of PET responders and 97.5% and 82.5% of PET nonresponders, with no new safety signals. The most common grade ≥3 TRAE was decreased neutrophil count (36.7% and 70.0%, respectively). Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.